Development of Dengue Vaccines – Status Review and Future Considerations
REPORT OF THE ASIA-PACIFIC DENGUE PREVENTION BOARD MEETING
Seoul, Korea November 21 – 22, 2014 :: 38 pages
Pdf: http://www.denguevaccines.org/sites/default/files/APDPB%202014%20report_final_3615.pdf
Overview
In November of 2014, DVI held a two-day meeting to discuss the status of a dengue vaccine and exchange views on its licensure and introduction. Members of the Asia-Pacific Dengue Prevention Board (DPB), modelers of the impact of vaccination on dengue, public health specialists and dengue vaccine candidate representatives contributed to these conversations.

The Board convened at a critical time — 2014 marked a milestone for the fight against dengue fever, with the first ever successful completion of Phase III clinical trials on a dengue vaccine candidate (CYD-TDV). These trials demonstrated that a vaccine that can prevent dengue cases is feasible, showing both safety and overall moderate efficacy, especially against the most severe outcomes of dengue infection, in both Asia and the Americas. At the same time, other vaccine candidates continued to progress in clinical development throughout the year, as did modeling of the impact of vaccination on dengue incidence.

These updates, and the new information they contribute to the field of dengue research, warrant a reassessment of the potential implications of dengue vaccine introduction in endemic countries. DVI will continue to support countries’ efforts to successfully plan for the introduction of dengue vaccines through evidenced-based research to help inform decision-making. One of these efforts is the upcoming Americas DPB meeting in March 16 and 17 in Bogota, Colombia. DVI looks forward to what is sure to be another productive exchange — one that can complement the conversations had in Seoul and raise points for further analysis, discussion, and knowledge sharing.

.
Professor Wilder-Smith Named New Senior Advisor to DVI
WASHINGTON, DC – March 6, 2015 – The members of the Dengue Vaccine Initiative (DVI) consortium, the International Vaccine Institute, the Johns Hopkins University International Vaccine Access Center, the Sabin Vaccine Institute and the World Health Organization, are delighted to announce the appointment of Professor Annelies Wilder-Smith as Senior Advisor to the DVI, effective immediately.

“We are extraordinarily pleased that Professor Wilder-Smith has joined us to provide guidance to DVI and ensure a smooth transition until a new full-time Director joins the Initiative. Her leadership in the research of dengue control and surveillance strategies will contribute to our efforts of laying the groundwork for the introduction of a dengue vaccine” said Dr. Jerome Kim, International Vaccine Institute Director General…